12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ASB17061: Phase II started

In its fiscal 3Q12 earnings ending Dec. 31, 2012, Daiichi said it began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 3...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >